Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for AZLF3004

Result Summary for AZLF3004

Result Summary

Protocol ID:	AZLF3004
Clinical Study ID:	ESS100327
Official Title:	An Open-label study to evaluate long-term (48 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF3004-Trisud
Phase:	Phase 3
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus I
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	Serevent
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Ragnaud JM, Delmas B, Gallais H, Peyramond D et al. Efficacy and Safety of Trizivir Maintenance Treatment After First-line Therapy. 6th International Congress on Drug Therapy in HIV Infection. Glasgow, November 17-21, 2002.